Bionomics’ BNC210 anti-anxiety drug enters phase I
Friday, 21 December, 2012
Bionomics’ (ASX:BNO) US partner, Ironwood Pharmaceuticals, has moved forward with development of anti-anxiety drug IW-2143, also known as BNC210, by initiating a phase I trial.
The company filed an Investigational New Drug application with the Food and Drug Administration in November.
The phase I trial will assess safety and pharmacokinetics of BNC210 in healthy volunteers using single and multiple doses.
“This is the first US clinical trial of IW-2143 and this news is welcomed by Bionomics as a strong signal of the progress being made by Ironwood in moving ahead with the study of IW-2143,” said Bionomics CEO and MD, Dr Deborah Rathjen.
Bionomics is expecting a US$2m milestone payment from Ironwood as the trial progresses.
Bionomics’ (ASX:BNO) lost half a cent in morning trading, sitting at 35c as of around 11am Friday.
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
